In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Flamel Technologies licenses BMS diabetes drug; terminated

Executive Summary

Drug delivery company Flamel Technologies SA licensed Bristol-Myers Squibb exclusive worldwide development and marketing rights to Basulin, its controlled-release human insulin candidate, which is ready to enter Phase II clinical trials for Types I and II diabetes. Basulin is a once-daily injection that uses Flamel's Medusa protein delivery technology.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register